Clinical characteristics of 144 patients with SLE
. | Total . |
|---|---|
| No. of patients | 144 |
| Women | 130 (90) |
| Age at study entry, y | 41 (19-76) |
| Age at diagnosis of SLE, y | 30 (9-73) |
| VTE | 15 (10) |
| ATE | 16 (11) |
| Fetal loss (% women) | 24 (18) |
| Both VTE and ATE | 2 (1) |
| Both VTE and fetal loss (% women) | 1 (1) |
| Both ATE and fetal loss (% women) | 5 (4) |
| Actual platelet number, × 109/L | 232 (44-576) |
| Thrombocytopenia, < 100 × 109/L | 2 (1) |
| Actual drug therapy | |
| Oral contraceptives (% women) | 23 (18) |
| Immunosuppressive drugs | 78 (54) |
| Oral anticoagulants | 12 (8) |
| SLEDAI score | 2 (0-25) |
| SLICC/ACR-DI score | 0 (0-5) |
. | Total . |
|---|---|
| No. of patients | 144 |
| Women | 130 (90) |
| Age at study entry, y | 41 (19-76) |
| Age at diagnosis of SLE, y | 30 (9-73) |
| VTE | 15 (10) |
| ATE | 16 (11) |
| Fetal loss (% women) | 24 (18) |
| Both VTE and ATE | 2 (1) |
| Both VTE and fetal loss (% women) | 1 (1) |
| Both ATE and fetal loss (% women) | 5 (4) |
| Actual platelet number, × 109/L | 232 (44-576) |
| Thrombocytopenia, < 100 × 109/L | 2 (1) |
| Actual drug therapy | |
| Oral contraceptives (% women) | 23 (18) |
| Immunosuppressive drugs | 78 (54) |
| Oral anticoagulants | 12 (8) |
| SLEDAI score | 2 (0-25) |
| SLICC/ACR-DI score | 0 (0-5) |
Continuous variables denoted as median (range), categorical variables as number (%).
VTE indicates venous thromboembolism; ATE, arterial thromboembolism; SLE-DAI, SLE Disease Activity Index; SLICC/ACR-DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.